$Emerging role of multikinase inhibitors for refractory thyroid cancer$
Código QR

Código QR

Emerging role of multikinase inhibitors for refractory thyroid cancer

Cesar A Perez,1 Belisario A Arango,1 Michel Velez,1 Luis E Raez,2 Edgardo S Santos11University of Miami Miller School of Medicine/Sylvester Comprehensive Cancer Center, Miami, USA; 2Memorial Cancer Institute, Memorial Health Care System, Hollywood, FL, USAAbstract: Thyroid cancer incidence continues...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Perez CA, Arango BA, Velez M, Raez LE, Santos ES
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2012
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/3179f4c79c1e45caa8c0a2a829772923
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Multikinase inhibitors in the treatment of thyroid cancer: specific role of lenvatinib
por: Stjepanovic N, et al.
Publicado: (2014)

Multikinase inhibitors use in differentiated thyroid carcinoma
por: Jasim S, et al.
Publicado: (2014)

Transferrin receptor-targeted HMSN for sorafenib delivery in refractory differentiated thyroid cancer therapy
por: Ke Y, et al.
Publicado: (2018)

Kinase-Inhibitors in Iodine-Refractory Differentiated Thyroid Cancer—Focus on Occurrence, Mechanisms, and Management of Treatment-Related Hypertension
por: Anne Christine Kaae, et al.
Publicado: (2021)

Role of vandetanib in the management of medullary thyroid cancer
por: Rondeau G, et al.
Publicado: (2012)

Evolutionary history expands the range of signaling interactions in hybrid multikinase networks
por: Philippe Ortet, et al.
Publicado: (2021)

Co-targeting PIM and PI3K/mTOR using multikinase inhibitor AUM302 and a combination of AZD-1208 and BEZ235 in prostate cancer
por: Sabina Luszczak, et al.
Publicado: (2020)

Bevacizumab in the therapy for refractory metastatic colorectal cancer
por: Mary F Mulcahy
Publicado: (2008)

Novel Inhibitor-Based Therapies for Thyroid Cancer—An Update
por: Maciej Ratajczak, et al.
Publicado: (2021)

Ixabepilone: a new chemotherapeutic option for refractory metastatic breast cancer
por: Shannon Puhalla, et al.
Publicado: (2008)

The emerging role of nimotuzumab in the treatment of non-small cell lung cancer
por: William Boland, et al.
Publicado: (2010)

The role of the size in thyroid cancer risk stratification
por: Federica Vianello, et al.
Publicado: (2021)

SARS-CoV-2: Emerging Role in the Pathogenesis of Various Thyroid Diseases
por: Murugan AK, et al.
Publicado: (2021)

Adjuvant treatment with thyrotropin alpha for remnant ablation in thyroid cancer
por: Bernadette Biondi, et al.
Publicado: (2008)

Management of bone metastases in refractory prostate cancer – role of denosumab
por: Paller CJ, et al.
Publicado: (2012)

Diabetic glomerulosclerosis can be the pathogenesis of refractory diabetic macular edema
por: Al Kahtani ES
Publicado: (2015)

The use of functional epirubicin liposomes to induce programmed death in refractory breast cancer
por: Liu L, et al.
Publicado: (2017)

Dasatinib in the treatment of imatinib refractory chronic myeloid leukemia
por: Radhakrishnan Ramchandren, et al.
Publicado: (2009)

Selenium and thyroid autoimmunity
por: Roberto Negro
Publicado: (2008)

Emerging nanotechnology approaches in tissue engineering and regenerative medicine
por: Kim ES, et al.
Publicado: (2014)

Platelet Activation and Inflammation in Patients with Papillary Thyroid Cancer
por: Sorina Martin, et al.
Publicado: (2021)

Emerging Role of PARP Inhibitors in Metastatic Triple Negative Breast Cancer. Current Scenario and Future Perspectives
por: Giacomo Barchiesi, et al.
Publicado: (2021)

Carfilzomib: A Promising Proteasome Inhibitor for the Treatment of Relapsed and Refractory Multiple Myeloma
por: Shansa Pranami E. Jayaweera, et al.
Publicado: (2021)

Relapsed and refractory lymphoid neoplasms and multiple myeloma with a focus on carfilzomib
por: Nooka A, et al.
Publicado: (2013)

First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors
por: Nguyen KS, et al.
Publicado: (2012)

Screening Leads to Overestimated Associations of Thyroid Dysfunction and Thyroiditis with Thyroid Cancer Risk
por: Young Shin Song, et al.
Publicado: (2021)

Treatment of refractory complex partial seizures: role of vigabatrin
por: Elizabeth J Waterhouse, et al.
Publicado: (2009)

Etiology of 305 cases of refractory hematospermia and therapeutic options by emerging endoscopic technology
por: Liang-Gong Liao, et al.
Publicado: (2019)

Alemtuzumab in the treatment of fludarabine refractory B-cell chronic lymphocytic leukemia (CLL)
por: Marco Montillo, et al.
Publicado: (2008)

Infliximab in treatment of idiopathic refractory childhood pyoderma gangrenosum (PG)
por: Salehzadeh F, et al.
Publicado: (2019)

Associated Factors in Response to Treatment in Children with Refractory Epilepsy
por: MM Nasehi, et al.
Publicado: (2010)

Small molecule tyrosine kinase inhibitors in pancreatic cancer
por: Sachin Gupta, et al.
Publicado: (2008)

Ovarian cancer: emerging molecular-targeted therapies
por: Sourbier C
Publicado: (2012)

Refractoriness of STING therapy is relieved by AKT inhibitor through effective vascular disruption in tumour
por: Seung-hwan Jeong, et al.
Publicado: (2021)

Differentiated thyroid cancer
por: Dmitrii G. Bel’tsevich, et al.
Publicado: (2021)

Rheumatic Manifestations and Diseases From Immune Checkpoint Inhibitors in Cancer Immunotherapy
por: Pan Shen, et al.
Publicado: (2021)

Predictors of Malignancy in Thyroid Nodules
por: Abdel Rahman Ahmed Mohamed Ragab, et al.
Publicado: (2021)

TIRADS effectiveness in cancer risk prognosis among patients with cystic and solid thyroid nodules
por: V.N. Marina, et al.
Publicado: (2018)

The role of thyroid stimulating hormone in the timing of thyroxin supplement after thyroid operations
por: Basil Abdulrazzaq Saadallah Al-Khayyat
Publicado: (2021)

Thyroid cancer MR molecular imaging via SHP2-targeted nanoparticles
por: Hu Z, et al.
Publicado: (2019)